The key findings of our study are that patients with T2D have elevated plasma ANXA1 levels, which correlate positively with fatty liver index and serum lipid levels, but not with markers of systemic inflammation, suggesting that the ANXA1 levels in patients with T2D are not regulated by systemic inflammation, but are a consequence of aberrant lipid handling. This evidence concerns the gene ANXA1 and type 2 diabetes mellitus.